Tags

Type your tag names separated by a space and hit enter

Chronic immune thrombocytopenia in a child responding only to thrombopoietin receptor agonist.
Sudan J Paediatr. 2012; 12(2):60-4.SJ

Abstract

Immune thrombocytopenia (ITP) is an acquired hematological disease in which the body produces antibodies against its own platelets leading to platelet destruction resulting in isolated thrombocytopenia. Childhood ITP may enter complete remission in the majority of cases within six months from diagnosis. However, 20-30% of affected children may develop chronic ITP (lasting for more than 12 months). First line treatment includes intravenous immunoglobulin (IVIG), corticosteroids or anti-D immunoglobulin. Second line treatment includes splenectomy, immunosuppressive therapy or Rituximab. Recently two thrombopoietin (TPO) receptor agonists (Romiplostim and Eltrombopag) are used to increase platelet count in refractory chronic ITP by increasing platelet production in bone marrow. Here is a case report on an 8 ½ -year-old boy with refractory chronic ITP who failed therapy with IVIG, corticosteroids, splenectomy and Rituximab. He showed excellent response to treatment with TPO receptor agonist (Romiplostim). His platelet count increased from less than 10 x10(3)/dl and maintained between 100x10(3)/dl to 200x10(3)/dl after few weeks of starting Romiplostim therapy.

Authors+Show Affiliations

Department of Pediatrics, College of Medicine , King Saud University, Riyadh , Saudi Arabia.

Pub Type(s)

Case Reports

Language

eng

PubMed ID

27493347

Citation

Osman, Mohamed E.. "Chronic Immune Thrombocytopenia in a Child Responding Only to Thrombopoietin Receptor Agonist." Sudanese Journal of Paediatrics, vol. 12, no. 2, 2012, pp. 60-4.
Osman ME. Chronic immune thrombocytopenia in a child responding only to thrombopoietin receptor agonist. Sudan J Paediatr. 2012;12(2):60-4.
Osman, M. E. (2012). Chronic immune thrombocytopenia in a child responding only to thrombopoietin receptor agonist. Sudanese Journal of Paediatrics, 12(2), 60-4.
Osman ME. Chronic Immune Thrombocytopenia in a Child Responding Only to Thrombopoietin Receptor Agonist. Sudan J Paediatr. 2012;12(2):60-4. PubMed PMID: 27493347.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Chronic immune thrombocytopenia in a child responding only to thrombopoietin receptor agonist. A1 - Osman,Mohamed E, PY - 2016/8/6/entrez PY - 2012/1/1/pubmed PY - 2012/1/1/medline KW - Immune thrombocytopenia KW - Platelet KW - Romiplostim SP - 60 EP - 4 JF - Sudanese journal of paediatrics JO - Sudan J Paediatr VL - 12 IS - 2 N2 - Immune thrombocytopenia (ITP) is an acquired hematological disease in which the body produces antibodies against its own platelets leading to platelet destruction resulting in isolated thrombocytopenia. Childhood ITP may enter complete remission in the majority of cases within six months from diagnosis. However, 20-30% of affected children may develop chronic ITP (lasting for more than 12 months). First line treatment includes intravenous immunoglobulin (IVIG), corticosteroids or anti-D immunoglobulin. Second line treatment includes splenectomy, immunosuppressive therapy or Rituximab. Recently two thrombopoietin (TPO) receptor agonists (Romiplostim and Eltrombopag) are used to increase platelet count in refractory chronic ITP by increasing platelet production in bone marrow. Here is a case report on an 8 ½ -year-old boy with refractory chronic ITP who failed therapy with IVIG, corticosteroids, splenectomy and Rituximab. He showed excellent response to treatment with TPO receptor agonist (Romiplostim). His platelet count increased from less than 10 x10(3)/dl and maintained between 100x10(3)/dl to 200x10(3)/dl after few weeks of starting Romiplostim therapy. SN - 0256-4408 UR - https://www.unboundmedicine.com/medline/citation/27493347/Chronic_immune_thrombocytopenia_in_a_child_responding_only_to_thrombopoietin_receptor_agonist_ L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/27493347/ DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.